Saturday, 3 October 2026
Electronic prescribing trial abandoned, Concurrent MenB vaccination safety, RACGP leads registrar experience
- 01
Electronic prescribing mandate trial abandoned as system fixes take priority
The Department of Health, Disability and Ageing has abandoned a planned trial that would have made electronic prescribing the default for certain medicines. Over the next 12 months, it will instead focus on Active Script List adoption, prescription token management, prescribing and dispensing workflows, and usability concerns raised by clinicians and patients, according to the AMA. The department said electronic prescribing by default had replaced the earlier plan for mandatory electronic prescribing of high-risk and high-cost medicines announced in the 2023–24 Budget. It remains committed to making electronic prescribing the national standard while retaining prescriber discretion to issue paper prescriptions when clinically necessary to support access and continuity of care. More than 370 million electronic prescriptions had been generated since 2021, according to an October 2025 Australian Digital Health Agency blog post cited in the article.
- 02
Concurrent MenB and routine infant vaccines did not increase adverse events
Giving meningococcal B (MenB) vaccine alongside routine National Immunisation Program vaccines did not increase reported adverse events in an Australian study of more than 10,000 infants. At two months, adverse events were reported in 29% of infants vaccinated concurrently, compared with 35% of those vaccinated at separate visits; at 12 months, the respective rates were 47% and 52%. The researchers said concurrent vaccination could also reduce appointments, time away from work and childcare, travel and healthcare costs, and the risk of children falling behind schedule. The Australian Immunisation Handbook recommends MenB vaccination for all infants and children aged under two years, with a two- or three-dose course depending on the age vaccination begins.
via RACGP newsGP
- 03
RACGP tops AMA registrar experience report card
The RACGP received the highest overall assessment in the AMA Specialist Trainee Experience Health Check, earning a B minus, while ACRRM placed second with a C plus. Across five dimensions and 23 criteria, the RACGP recorded average or significantly more favourable feedback on all but one criterion, with payment for unrostered overtime its only significantly less favourable result. It led on work–life balance, with around 80% of registrars rating this positively, while agreement that the college sought registrar views rose from just over 35% in 2019 to more than 60% in 2025. ACRRM performed best on exam feedback, with more than 60% reporting useful feedback and close to 70% reporting timely feedback. Based on AHPRA’s 2025 Medical Training Survey, the independent analysis found exam feedback remained a common concern across colleges, with 39% reporting useful feedback and 44% reporting timely feedback.
- 04
FDA approves expandable synthetic pulmonary valve for children
The US Food and Drug Administration has approved Edwards Lifesciences’ Autus pulmonary valve, which can be expanded as a child grows to reduce repeat open-heart surgery. Surgically implanted at about 13 mm in diameter, it can later be widened by balloon catheter to 22 mm and is the first approved valve in any indication to use synthetic polymer rather than animal tissue for its leaflets. Approval was based on a pivotal study of 62 children in which all procedures were successful; at six months, the first 60 patients had acceptable right-sided blood flow and no more than mild valve leakage. Three patients had valve-frame fractures and two had reduced movement of one leaflet, without symptoms, while two valves that deteriorated as patients began to outgrow them were successfully expanded without invasive surgery. One-year follow-up suggested the synthetic leaflets were holding up well, and participants will be followed for 10 years.
via MedTech Dive
- 05
FDA prioritises AI and surgical robot guidance for 2027
The US Food and Drug Administration has prioritised final guidance on marketing submissions and lifecycle management for AI-enabled devices in fiscal 2027. It also plans to draft evidentiary recommendations for generative AI-enabled conversational devices used for mental disorders. Guidance on premarket submissions for certain robotically assisted surgical devices is also slated for finalisation, covering nonclinical testing, clinical data and labelling. Second-tier priorities include final guidance on pulse oximeter performance testing, labelling and premarket submissions, following concerns about the effect of skin pigmentation on accuracy. The FDA is accepting feedback on its overall priorities until 30 November and on the surgical robotics draft until 24 November.
via MedTech Dive
- 06
RACGP calls for national standards linking urgent care to practices
Urgent care services should operate under nationally consistent, profession-led standards and maintain strong links with patients’ usual general practices or Aboriginal Community Controlled Health Organisations, the RACGP says. Its new position statement identifies urgent care as a core part of general practice and calls for clear clinical governance, supervision, escalation processes, communication and reliable transfer of patient information. A recent evaluation found reasonably strong evidence that urgent care clinics reduced urgent care-style hospital presentations by up to 10%, but only 65% of presentations included a handover to the patient’s usual GP or practice. The college also recommends flexible funding across general practices, ACCHOs and dedicated clinics, alongside MBS after-hours reforms that would start the weekday after-hours period at 5 pm and include all of Saturday. It is examining evidence gaps including cost-effectiveness, longer-term outcomes, health inequities and effects on continuity of care.
via RACGP newsGP
MDDR is a news digest for medical professionals. It is not medical advice and should not be relied on for clinical decision-making.